Comparison of Tolerability Between Two Allergy Drops

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01390961

Enrollment

Registered

2011-07-11

Start date

2011-08-31

Completion date

2012-01-31

Last updated

2011-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Conjunctivitis

Keywords

Allergic conjunctivitis

Brief summary

Comfort is compared between two allergy drops

Interventions

DRUGalacaftadine and naphazoline HCl & pheniramine maleate

once a day

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Months to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Between the ages of 18 and over inclusive. * Males or females * Patient is in generally good & stable overall health. * Patient likely to comply with study guidelines & study visits. * Informed consent signed. * History of allergic conjunctivitis * Current symptoms of allergic conjunctivitis assessed by the investigator

Exclusion criteria

* Corneal refractive surgery or contact lens wear within 6 months of this study. * Current use of Restasis * Intra-ocular surgery within 6 months or ocular laser surgery within 6 months. * Pregnant or lactating women. * Ocular pathology (includes glaucoma and cataract), which could impact results and/or place patient at risk.

Design outcomes

Primary

Measure	Time frame	Description
Tolerability	8 weeks	Tolerability measured by questionnaire Visual Analog scale 1 to 100

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026